½ÃÀ庸°í¼­
»óǰÄÚµå
1475189

¼¼°èÀÇ ÀüÀÚó¹æ(ePrescribing) ½ÃÀå Á¶»ç º¸°í¼­ : »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ, ¿¹Ãø(2024-2032³â)

Global ePrescribing Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Value Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 233 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ ÀüÀÚó¹æ(ePrescribing) ½ÃÀå ¼ö¿ä´Â 2023³â 30¾ï 7,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2032³â¿¡´Â 159¾ï 5,000¸¸ ´Þ·¯ ±Ùó ½ÃÀå ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ÃßÁ¤µÇ¸ç, Á¶»ç ±â°£ 2024³âºÎÅÍ 2032³â±îÁö CAGRÀº 20.09%·Î Àü¸ÁµË´Ï´Ù.

ePrescribingÀ̶õ electronic prescribing(ÀüÀÚ Ã³¹æ)ÀÇ ¾àÀÚ·Î ÀÇ·á Á¦°ø¾÷ü°¡ ÀüÀÚ ÀÇ·á ±â·Ï(EHR) ½Ã½ºÅÛÀ̳ª ÀüÀÚ Ã³¹æ ¼ÒÇÁÆ®¿þ¾î·ÎºÎÅÍ Á÷Á¢ ó¹æÀüÀ» ÀÛ¼ºÇÏ¿© ¾à±¹¿¡ Àü¼ÛÇÒ ¼ö ÀÖµµ·Ï ÇÏ´Â µðÁöÅÐ ÀÇ·á ±â¼úÀÔ´Ï´Ù. ÀÌ °úÁ¤Àº Á¾ÀÌ ±â¹Ý ó¹æÀüÀ» ÇÊ¿ä·Î ÇÏÁö ¾ÊÀ¸¸ç ½Ç¼ö¸¦ ÁÙÀ̰í È¿À²¼ºÀ» Çâ»ó½Ã۰í ȯÀÚÀÇ ¾ÈÀü¼ºÀ» ³ôÀÔ´Ï´Ù. ÀÇ·á Á¦°ø¾÷ü´Â ȯÀÚÀÇ ¾à·Â¿¡ ¾×¼¼½ºÇϰí, ¾à¹° »óÈ£ÀÛ¿ëÀ» ½ºÅ©¸®´×Çϰí, ó¹æÀüÀ» ¾ÈÀüÇÏ°Ô ¾à±¹¿¡ º¸³¾ ¼ö ÀÖÀ¸¸ç, ¾à¹° °ü¸® ÇÁ·Î¼¼½º¸¦ °£¼ÒÈ­ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÇ·á Á¦°ø¾÷ü °£ÀÇ ÄÉ¾î ¿¬°è¸¦ ÃËÁøÇϰí ȯÀÚÀÇ º¹¾à Áؼö¸¦ Çâ»ó½ÃÅ´À¸·Î½á, ÀÇ·á °á°úÀÇ °³¼±°ú º¹¾à °ü¸®ÀÇ È¿À²È­·Î À̾îÁý´Ï´Ù.

½ÃÀå ¿ªÇÐ

ÀÇ·á ½Ã½ºÅÛÀÇ µðÁöÅÐÈ­ ¹× ÀüÀÚ ÀÇ·á ±â·Ï(EHR)ÀÇ Ã¤ÅÃÀº ÀüÀÚ Ã³¹æ ¼Ö·ç¼Ç ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÇ·á Àü¹®°¡µéÀº Åõ¾à ¾ÈÀü¼º Çâ»ó, È¿À²¼º °­È­, Åõ¾à ½Ç¼ö °¨¼Ò µî ÀüÀÚ Ã³¹æÀÇ ÀåÁ¡À» Á¡Á¡ ÀνÄÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ȯÀÚ ÄɾîÀÇ Çâ»ó, ÀÇ·áºñÀÇ Àý°¨, 󹿾àÀÇ ³²¿ë ¹Ú¸êÀ» ¸ñÀûÀ¸·Î ÇÑ ÀüÀÚ Ã³¹æ ½Ã½ºÅÛÀ» ÃßÁøÇÏ´Â Á¤ºÎÀÇ ´ëó³ª ±ÔÁ¦°¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ePrescribing ¼Ö·ç¼ÇÀ» ¾à±¹ ½Ã½ºÅÛ, ÀüÀÚ ÀÇ·á ±â·Ï, ÀÓ»ó ÀÇ»ç °áÁ¤ Áö¿ø µµ±¸¿Í ÅëÇÕÇÏ¸é ±â´É°ú »ç¿ë¼ºÀÌ È®´ëµÇ°í ÀÇ·á Á¦°ø¾÷ü °£ÀÇ Ã¤¿ëÀÌ ÃËÁøµË´Ï´Ù. °Ô´Ù°¡ COVID-19ÀÇ ´ëÀ¯ÇàÀº ¿ø°Ý ÀÇ·á ¹× ¿ø°Ý ÀÇ·á ¼­ºñ½ºÀÇ µµÀÔÀ» ¼­µÎ¸£°í º¥´õ°¡ ÅëÇÕ ¿ø°Ý ÀÇ·á ¼Ö·ç¼ÇÀ» Á¦°øÇÒ ±âȸ¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù. ¸ð¹ÙÀÏ ¾ÖÇø®ÄÉÀ̼Ç, ÀüÀÚ »çÀü ½ÂÀÎ ±â´É, »óÈ£ ¿î¿ë¼º Ç¥ÁØ µîÀÇ ±â¼úÀû Áøº¸°¡ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ±×·¯³ª »óÈ£ ¿î¿ë¼º ¹®Á¦¿Í µ¥ÀÌÅÍ º¸¾È¿¡ ´ëÇÑ ¿ì·Á°¡ ÇâÈÄ ¼ö³â°£ ½ÃÀå ¼ºÀåÀÇ °úÁ¦°¡ µÉ ¼ö ÀÖ½À´Ï´Ù.

Á¶»ç º¸°í¼­´Â Porter's Five Forces ¸ðµ¨, ½ÃÀå ¸Å·Âµµ ºÐ¼®, ¹ë·ùüÀÎ ºÐ¼®À» ´Ù·ç°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µµ±¸´Â ¾÷°èÀÇ ±¸Á¶¸¦ ¸íÈ®ÇÏ°Ô ÆÄ¾ÇÇÏ°í ¼¼°è ¼öÁØÀÇ °æÀïÀÇ ¸Å·ÂÀ» Æò°¡ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¶ÇÇÑ ÀÌ·¯ÇÑ µµ±¸´Â ¼¼°èÀÇ ÀüÀÚó¹æ(ePrescribing) ½ÃÀå¿¡¼­ °¢ ºÎ¹®À» Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ePrescribing »ê¾÷ÀÇ ¼ºÀå°ú µ¿ÇâÀº ÀÌ ¿¬±¸¿¡ ´ëÇÑ Àü¹ÝÀûÀÎ Á¢±Ù¹ýÀ» ¼³¸íÇÕ´Ï´Ù.

½ÃÀå ¼¼ºÐÈ­

ÀüÀÚó¹æ(ePrescribing) ½ÃÀå º¸°í¼­ÀÇ ÀÌ ¼½¼Ç¿¡¼­´Â ±¹°¡ ¹× Áö¿ª ¼öÁØÀÇ ºÎ¹®¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ µ¥ÀÌÅ͸¦ Á¦°øÇÏ¿© Àü·«°¡°¡ °¢ Á¦Ç° ¹× ¼­ºñ½ºÀÇ ´ë»ó °èÃþÀ» ½Äº°ÇÏ´Â µ¥ ¹Ì·¡ÀÇ ºñÁî´Ï½º ±âȸ¸¦ Áö¿øÇÕ´Ï´Ù.

Á¦Ç°º°

  • ¼Ö·ç¼Ç(ÅëÇÕ ¼Ö·ç¼Ç, µ¶¸³Çü ¼Ö·ç¼Ç)
  • ¼­ºñ½º(Áö¿ø, ±¸Çö, ±³À°, ³×Æ®¿öÅ©)

Àü°³ ¸ðµåº°

  • À¥ ¹× Ŭ¶ó¿ìµå ±â¹Ý
  • ¿ÂÇÁ·¹¹Ì½º

¹°Áúº°

  • ±ÔÁ¦ ¹°Áú
  • ºñ±ÔÁ¦ ¹°Áú

¿ëµµº°

  • ÇÚµåÇïµå
  • ÄÄÇ»ÅÍ ±â¹Ý ±â±â

Àü¹® ºÐ¾ßº°

  • Á¾¾çÇÐ
  • ½ºÆ÷Ã÷ ÀÇ·á
  • ½Å°æÇÐ
  • ¼øÈ¯±â°ú
  • ±âŸ

ÃÖÁ¾ ¿ëµµº°

  • º´¿ø
  • ±Ù¹«ÀÇ
  • ¾à±¹
  • ±âŸ

Áö¿ª ºÐ¼®

ÀÌ ¼½¼Ç¿¡¼­´Â ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«¿¡¼­ ÀüÀÚó¹æ(ePrescribing) ½ÃÀåÀÇ ÇöÀç ¹× ¹Ì·¡ ¼ö¿ä¸¦ °­Á¶ÇÏ´Â Áö¿ª Àü¸ÁÀ» ´Ù·ì´Ï´Ù. ¶ÇÇÑ, Àú¸íÇÑ ¸ðµç Áö¿ª¿¡¼­ÀÇ °³º° ¿ëµµ ºÎ¹® ¼ö¿ä, ÃßÁ¤ ¹× ¿¹Ãø¿¡µµ ÃÊÁ¡À» ¸ÂÃß¾ú½À´Ï´Ù.

¸ÂÃ㠿䱸»çÇ×ÀÌ ÀÖ´Â °æ¿ì Google¿¡ ¹®ÀÇÇϼ¼¿ä. ´ç»çÀÇ ¼³¹®Á¶»çÆÀÀº °í°´ÀÇ ¿ä±¸¿¡ µû¶ó ¸ÂÃãÇü º¸°í¼­¸¦ Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • ½ÃÀåÀÇ ÇÏÀ̶óÀÌÆ®
  • ¼¼°è ½ÃÀå ÇöȲ

Á¦3Àå ePrescribing : »ê¾÷ ºÐ¼®

  • ¼­¹® : ½ÃÀå ¿ªÇÐ
  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ±âȸ
  • ¾÷°è µ¿Çâ
  • Porter's Five Forces ºÐ¼®
  • ½ÃÀå ¸Å·Âµµ ºÐ¼®

Á¦4Àå ¹ë·ùüÀÎ ºÐ¼®

  • ¹ë·ùüÀÎ ºÐ¼®
  • ¿øÀç·á ºÐ¼®
    • ¿øÀç·á ¸®½ºÆ®
    • ¿øÀç·á Á¦Á¶¾÷ü À϶÷
    • ÁÖ¿ä ¿øÀç·áÀÇ °¡°Ý µ¿Çâ
  • ÀáÀçÀû ¹ÙÀ̾î À϶÷
  • ¸¶ÄÉÆÃ Ã¤³Î
    • Á÷Á¢ ¸¶ÄÉÆÃ
    • °£Á¢ ¸¶ÄÉÆÃ
    • ¸¶ÄÉÆÃ Ã¤³Î ¹ßÀü µ¿Çâ

Á¦5Àå ¼¼°èÀÇ ÀüÀÚó¹æ(ePrescribing) ½ÃÀå ºÐ¼® : Á¦Ç°º°

  • Á¦Ç°º° °³¿ä
  • ½ÇÀû µ¥ÀÌÅÍ ¹× ¿¹Ãø µ¥ÀÌÅÍ
  • Á¦Ç°º° ºÐ¼®
  • ¼Ö·ç¼Ç(ÅëÇÕ ¼Ö·ç¼Ç, µ¶¸³Çü ¼Ö·ç¼Ç)
  • ¼­ºñ½º(Áö¿ø, µµÀÔ, ±³À°, ³×Æ®¿öÅ©)

Á¦6Àå ¼¼°èÀÇ ÀüÀÚó¹æ(ePrescribing) ½ÃÀå ºÐ¼® : Àü°³ ¸ðµåº°

  • Àü°³ ¸ðµåº° °³¿ä
  • ½ÇÀû µ¥ÀÌÅÍ ¹× ¿¹Ãø µ¥ÀÌÅÍ
  • Àü°³ ¸ðµåº° ºÐ¼®
  • À¥ ¹× Ŭ¶ó¿ìµå ±â¹Ý
  • ¿ÂÇÁ·¹¹Ì½º

Á¦7Àå ¼¼°èÀÇ ÀüÀÚó¹æ(ePrescribing) ½ÃÀå ºÐ¼® : ¹°Áúº°

  • ¹°Áúº° °³¿ä
  • ½ÇÀû µ¥ÀÌÅÍ ¹× ¿¹Ãø µ¥ÀÌÅÍ
  • ¹°Áúº° ºÐ¼®
  • ±ÔÁ¦ ¹°Áú
  • ºñ±ÔÁ¦ ¹°Áú

Á¦8Àå ¼¼°èÀÇ ÀüÀÚó¹æ(ePrescribing) ½ÃÀå ºÐ¼® : ¿ëµµº°

  • ¿ëµµº° °³¿ä
  • ½ÇÀû µ¥ÀÌÅÍ ¹× ¿¹Ãø µ¥ÀÌÅÍ
  • ¿ëµµº° ºÐ¼®
  • ÇÚµåÇïµå
  • ÄÄÇ»ÅÍ ±â¹Ý ±â±â

Á¦9Àå ePrescribing ¼¼°è ½ÃÀå ºÐ¼® : Àü¹® ºÐ¾ßº°

  • °³¿ä Àü¹® ºÐ¾ßº°
  • ½ÇÀû µ¥ÀÌÅÍ ¹× ¿¹Ãø µ¥ÀÌÅÍ
  • Àü¹® ºÐ¾ßº° ºÐ¼®
  • Á¾¾çÇÐ
  • ½ºÆ÷Ã÷ ÀÇ·á
  • ½Å°æÇÐ
  • ¼øÈ¯±â ³»°ú
  • ±âŸ

Á¦10Àå ePrescribing ¼¼°è ½ÃÀå ºÐ¼® : ÃÖÁ¾ ¿ëµµº°

  • ¿ëµµº° °³¿ä
  • ½ÇÀû µ¥ÀÌÅÍ ¹× ¿¹Ãø µ¥ÀÌÅÍ
  • ÃÖÁ¾ ¿ëµµº° ºÐ¼®
  • º´¿ø
  • »ç¹«½Ç ±â¹ÝÀÇ ÀÇ»ç
  • ¾à±¹
  • ±âŸ

Á¦11Àå ¼¼°èÀÇ ÀüÀÚó¹æ(ePrescribing) ½ÃÀå ºÐ¼® : Áö¿ªº°

  • Áö¿ªº° Àü¸Á
  • ¼­¹®
  • ºÏ¹ÌÀÇ ¸ÅÃ⠺м®
    • °³¿ä, ½ÇÀû ¹× ¿¹Ãø
    • ºÏ¹Ì : ºÎ¹®º°
    • ºÏ¹Ì : ±¹°¡º°
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´ÀÇ ¸ÅÃ⠺м®
    • °³¿ä, ½ÇÀû ¹× ¿¹Ãø
    • À¯·´ : ºÎ¹®º°
    • À¯·´ : ±¹°¡º°
    • ¿µ±¹
    • ÇÁ¶û½º
    • µ¶ÀÏ
    • ÀÌÅ»¸®¾Æ
    • ·¯½Ã¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¸ÅÃ⠺м®
    • °³¿ä, ½ÇÀû ¹× ¿¹Ãø
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ºÎ¹®º°
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ±¹°¡º°
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • Çѱ¹
    • È£ÁÖ
    • µ¿³²¾Æ½Ã¾Æ
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ ¸ÅÃ⠺м®
    • °³¿ä, ½ÇÀû ¹× ¿¹Ãø
    • ¶óƾ¾Æ¸Þ¸®Ä« : ºÎ¹®º°
    • ¶óƾ¾Æ¸Þ¸®Ä« : ±¹°¡º°
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
    • Æä·ç
    • Ä¥·¹
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ¸ÅÃ⠺м®
    • °³¿ä, ½ÇÀû ¹× ¿¹Ãø
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ºÎ¹®º°
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ±¹°¡º° À϶÷
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • À̽º¶ó¿¤
    • ³²¾ÆÇÁ¸®Ä«
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦12Àå ePrescribing ±â¾÷°æÀï ±¸µµ

  • ÀüÀÚó¹æ(ePrescribing) ½ÃÀå °æÀï
  • ÆÄÆ®³Ê½Ê, Á¦ÈÞ ¹× ÇÕÀÇ
  • ÇÕº´ ¹× Àμö
  • ½ÅÁ¦Ç° ¹ß¸Å
  • ±âŸ °³¹ß

Á¦13Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

  • ÁÖ¿ä ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®
  • ½ÃÀå ÁýÁßµµ
  • Allscripts Healthcare LLC
  • Athenahealth
  • Change Healthcare
  • DrFirst
  • Epic Systems Corporation
  • McKesson Corporation
  • Networking Technology Inc.
  • NXGN Management LLC
  • Practice Fusion Inc.
  • Surescripts.
AJY 24.05.20

The global demand for ePrescribing Market is presumed to reach the market size of nearly USD 15.95 Billion by 2032 from USD 3.07 Billion in 2023 with a CAGR of 20.09% under the study period 2024 - 2032.

ePrescribing, short for electronic prescribing, is a digital healthcare technology enabling healthcare providers to generate and transmit prescriptions to pharmacies directly from their electronic health record (EHR) systems or electronic prescribing software. This process eliminates the need for paper-based prescriptions, reducing errors, improving efficiency, and enhancing patient safety. It allows healthcare providers to access patient medication histories, screen for drug interactions, and send prescriptions securely to pharmacies, streamlining the medication management process. Additionally, it promotes better coordination of care among healthcare providers and facilitates medication adherence by patients, leading to improved healthcare outcomes and medication management efficiency.

MARKET DYNAMICS

The digitization of healthcare systems and adopting electronic health records (EHRs) drive the demand for electronic prescribing solutions. Healthcare professionals increasingly acknowledge the benefits of ePrescribing, such as improved medication safety, enhanced efficiency, and reduced medication errors. Additionally, government initiatives and regulations promoting ePrescribing systems to improve patient care, reduce healthcare costs, and combat prescription drug abuse fuel market growth. Moreover, integrating ePrescribing solutions with pharmacy systems, electronic medical records, and clinical decision support tools expands their functionality and usability, driving adoption among healthcare providers. Furthermore, the COVID-19 pandemic has hastened the adoption of telehealth and remote healthcare services, creating opportunities for vendors to offer integrated telemedicine solutions. Technological advancements such as mobile applications, electronic prior authorization capabilities, and interoperability standards contribute to market growth. However, interoperability issues and concerns about data security may challenge the market growth in the coming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of eprescribing. The growth and trends of eprescribing industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the eprescribing market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product

  • Solutions (Integrated Solutions, Standalone Solutions)
  • Services (Support, Implementation, Training, Network)

By Delivery Mode

  • Web/Cloud-Based
  • On-Premises

By Substances

  • Controlled Substances
  • Non-Controlled Substances

By Usage

  • Handheld
  • Computer-Based Devices

By Specialties

  • Oncology
  • Sports Medicine
  • Neurology
  • Cardiology
  • Other

By End-Use

  • Hospital
  • Office-Based Physicians
  • Pharmacy
  • Other

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the ePrescribing market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the ePrescribing market include Allscripts Healthcare, LLC, Athenahealth, Change Healthcare, DrFirst, Epic Systems Corporation, McKesson Corporation, Networking Technology, Inc., NXGN Management, LLC, Practice Fusion, Inc., Surescripts. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. EPRESCRIBING - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Product
    • 3.7.2 Market Attractiveness Analysis By Delivery Mode
    • 3.7.3 Market Attractiveness Analysis By Substances
    • 3.7.4 Market Attractiveness Analysis By Usage
    • 3.7.5 Market Attractiveness Analysis By Specialties
    • 3.7.6 Market Attractiveness Analysis By End-use
    • 3.7.7 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL EPRESCRIBING MARKET ANALYSIS BY PRODUCT

  • 5.1. Overview By Product
  • 5.2. Historical and Forecast Data
  • 5.3. Analysis By Product
  • 5.4. Solutions (Integrated Solutions, Standalone Solutions) Historic and Forecast Sales By Regions
  • 5.5. Services (Support, Implementation, Training, Network) Historic and Forecast Sales By Regions

6. GLOBAL EPRESCRIBING MARKET ANALYSIS BY DELIVERY MODE

  • 6.1. Overview By Delivery Mode
  • 6.2. Historical and Forecast Data
  • 6.3. Analysis By Delivery Mode
  • 6.4. Web/Cloud-Based Historic and Forecast Sales By Regions
  • 6.5. On-Premises Historic and Forecast Sales By Regions

7. GLOBAL EPRESCRIBING MARKET ANALYSIS BY SUBSTANCES

  • 7.1. Overview By Substances
  • 7.2. Historical and Forecast Data
  • 7.3. Analysis By Substances
  • 7.4. Controlled Substances Historic and Forecast Sales By Regions
  • 7.5. Non-Controlled Substances Historic and Forecast Sales By Regions

8. GLOBAL EPRESCRIBING MARKET ANALYSIS BY USAGE

  • 8.1. Overview By Usage
  • 8.2. Historical and Forecast Data
  • 8.3. Analysis By Usage
  • 8.4. Handheld Historic and Forecast Sales By Regions
  • 8.5. Computer-Based Devices Historic and Forecast Sales By Regions

9. GLOBAL EPRESCRIBING MARKET ANALYSIS BY SPECIALTIES

  • 9.1. Overview By Specialties
  • 9.2. Historical and Forecast Data
  • 9.3. Analysis By Specialties
  • 9.4. Oncology Historic and Forecast Sales By Regions
  • 9.5. Sports Medicine Historic and Forecast Sales By Regions
  • 9.6. Neurology Historic and Forecast Sales By Regions
  • 9.7. Cardiology Historic and Forecast Sales By Regions
  • 9.8. Other Historic and Forecast Sales By Regions

10. GLOBAL EPRESCRIBING MARKET ANALYSIS BY END-USE

  • 10.1. Overview By End-use
  • 10.2. Historical and Forecast Data
  • 10.3. Analysis By End-use
  • 10.4. Hospital Historic and Forecast Sales By Regions
  • 10.5. Office-Based Physicians Historic and Forecast Sales By Regions
  • 10.6. Pharmacy Historic and Forecast Sales By Regions
  • 10.7. Other Historic and Forecast Sales By Regions

11. GLOBAL EPRESCRIBING MARKET ANALYSIS BY GEOGRAPHY

  • 11.1. Regional Outlook
  • 11.2. Introduction
  • 11.3. North America Sales Analysis
    • 11.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 11.3.2 North America By Segment Sales Analysis
    • 11.3.3 North America By Country Sales Analysis
    • 11.3.4 United States Sales Analysis
    • 11.3.5 Canada Sales Analysis
    • 11.3.6 Mexico Sales Analysis
  • 11.4. Europe Sales Analysis
    • 11.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 11.4.2 Europe By Segment Sales Analysis
    • 11.4.3 Europe By Country Sales Analysis
    • 11.4.4 United Kingdom Sales Analysis
    • 11.4.5 France Sales Analysis
    • 11.4.6 Germany Sales Analysis
    • 11.4.7 Italy Sales Analysis
    • 11.4.8 Russia Sales Analysis
    • 11.4.9 Rest Of Europe Sales Analysis
  • 11.5. Asia Pacific Sales Analysis
    • 11.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 11.5.2 Asia Pacific By Segment Sales Analysis
    • 11.5.3 Asia Pacific By Country Sales Analysis
    • 11.5.4 China Sales Analysis
    • 11.5.5 India Sales Analysis
    • 11.5.6 Japan Sales Analysis
    • 11.5.7 South Korea Sales Analysis
    • 11.5.8 Australia Sales Analysis
    • 11.5.9 South East Asia Sales Analysis
    • 11.5.10 Rest Of Asia Pacific Sales Analysis
  • 11.6. Latin America Sales Analysis
    • 11.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 11.6.2 Latin America By Segment Sales Analysis
    • 11.6.3 Latin America By Country Sales Analysis
    • 11.6.4 Brazil Sales Analysis
    • 11.6.5 Argentina Sales Analysis
    • 11.6.6 Peru Sales Analysis
    • 11.6.7 Chile Sales Analysis
    • 11.6.8 Rest of Latin America Sales Analysis
  • 11.7. Middle East & Africa Sales Analysis
    • 11.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 11.7.2 Middle East & Africa By Segment Sales Analysis
    • 11.7.3 Middle East & Africa By Country Sales Analysis
    • 11.7.4 Saudi Arabia Sales Analysis
    • 11.7.5 UAE Sales Analysis
    • 11.7.6 Israel Sales Analysis
    • 11.7.7 South Africa Sales Analysis
    • 11.7.8 Rest Of Middle East And Africa Sales Analysis

12. COMPETITIVE LANDSCAPE OF THE EPRESCRIBING COMPANIES

  • 12.1. EPrescribing Market Competition
  • 12.2. Partnership/Collaboration/Agreement
  • 12.3. Merger And Acquisitions
  • 12.4. New Product Launch
  • 12.5. Other Developments

13. COMPANY PROFILES OF EPRESCRIBING INDUSTRY

  • 13.1. Top Companies Market Share Analysis
  • 13.2. Market Concentration Rate
  • 13.3. Allscripts Healthcare LLC
    • 13.3.1 Company Overview
    • 13.3.2 Company Revenue
    • 13.3.3 Products
    • 13.3.4 Recent Developments
  • 13.4. Athenahealth
    • 13.4.1 Company Overview
    • 13.4.2 Company Revenue
    • 13.4.3 Products
    • 13.4.4 Recent Developments
  • 13.5. Change Healthcare
    • 13.5.1 Company Overview
    • 13.5.2 Company Revenue
    • 13.5.3 Products
    • 13.5.4 Recent Developments
  • 13.6. DrFirst
    • 13.6.1 Company Overview
    • 13.6.2 Company Revenue
    • 13.6.3 Products
    • 13.6.4 Recent Developments
  • 13.7. Epic Systems Corporation
    • 13.7.1 Company Overview
    • 13.7.2 Company Revenue
    • 13.7.3 Products
    • 13.7.4 Recent Developments
  • 13.8. McKesson Corporation
    • 13.8.1 Company Overview
    • 13.8.2 Company Revenue
    • 13.8.3 Products
    • 13.8.4 Recent Developments
  • 13.9. Networking Technology Inc.
    • 13.9.1 Company Overview
    • 13.9.2 Company Revenue
    • 13.9.3 Products
    • 13.9.4 Recent Developments
  • 13.10. NXGN Management LLC
    • 13.10.1 Company Overview
    • 13.10.2 Company Revenue
    • 13.10.3 Products
    • 13.10.4 Recent Developments
  • 13.11. Practice Fusion Inc.
    • 13.11.1 Company Overview
    • 13.11.2 Company Revenue
    • 13.11.3 Products
    • 13.11.4 Recent Developments
  • 13.12. Surescripts.
    • 13.12.1 Company Overview
    • 13.12.2 Company Revenue
    • 13.12.3 Products
    • 13.12.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦